Invitrogen has introduced two new RNAi research vectors.
Â
The first, Block-iT HiPerform Lentiviral Pol-II miR RNAi expression system with Emerald Green Fluorescent Protein, can be used to deliver to non-dividing, primary, and hard-to-transfect cells, Invitrogen said.
Â
The second, Block-iT Inducible Pol-II miR RNAi expression system, uses a tetracycline-inducible promoter that allows researchers to control RNAi expression.
Â
Â
Altogen Biosystems has introduced new contract research services for RNAi including transfection services, assay development and library screening, cloning and vector construction, stable cell-line generation, and RNAi and gene-targeting experiments.
Â
Â
Thermo Fisher Scientific has introduced the Dharmacon Accell siRNA, a novel form of siRNA that is absorbed directly by cells without the use of conventional delivery methods such as transfection reagents, viruses, or electroporation.
Â
According to the company, the siRNA can silence genes in all cell types tested to date when mixed with the optimized Accell delivery media and added to cultured cells.